<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573777</url>
  </required_header>
  <id_info>
    <org_study_id>00121763</org_study_id>
    <nct_id>NCT04573777</nct_id>
    <nct_alias>NCT04573010</nct_alias>
  </id_info>
  <brief_title>Reducing Intracranial atheroSclErosis With Repatha</brief_title>
  <acronym>RISER</acronym>
  <official_title>Reducing Intracranial atheroSclErosis With Repatha</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adam de Havenon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to understand the underlying mechanism by which PCSK9&#xD;
      inhibition reduces the rate of ischemic stroke seen in the pivotal studies that led to its&#xD;
      FDA approval for ASCVD such as ischemic stroke. Those trials (FOURIER and ODYSSEY) enrolled&#xD;
      almost 50,000 patients and showed that PCSK9 inhibition therapy is safe and effective. The&#xD;
      investigators hypothesize that PCSK9 inhibition lowers the rate of stroke by reducing&#xD;
      atherosclerotic plaque, which would be particularly beneficial for patients with intracranial&#xD;
      atherosclerosis, who have the highest rate of recurrent stroke of any stroke mechanism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stenosis</measure>
    <time_frame>1.5 years</time_frame>
    <description>Measured on ToF MRA, CE-MRA, T1 Dante</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent atheroma volume</measure>
    <time_frame>1.5 years</time_frame>
    <description>Measured on ToF MRA, CE-MRA, T1/T2/PD Dante</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ischemic Stroke</measure>
    <time_frame>1.5 years</time_frame>
    <description>Adjudicated</description>
  </other_outcome>
  <other_outcome>
    <measure>ITA</measure>
    <time_frame>1.5 years</time_frame>
    <description>Adjudicated</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention Repatha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repatha</intervention_name>
    <description>140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor</description>
    <arm_group_label>Intervention Repatha</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients, ≥ 18 years of age&#xD;
&#xD;
          -  History of ischemic stroke, defined as an episode of neurological dysfunction caused&#xD;
             by focal cerebral, spinal, or retinal infarction (American Heart Association&#xD;
             definition).&#xD;
&#xD;
          -  Large vessel atherosclerosis of an intracranial artery in the circle of Willis with&#xD;
             50-99% stenosis by WASID criteria (percent stenosis = (1-[diameter stenosis/diameter&#xD;
             normal]) x 100%) on MRA, CTA or DSA&#xD;
&#xD;
             ------ Eligible arteries: vertebral (V4), basilar, PCA (P1, P2), MCA (M1, M2), tICA,&#xD;
             ACA (A1)&#xD;
&#xD;
          -  Current statin use or contraindication to statin&#xD;
&#xD;
          -  Fasting LDL-C ≥ 70 mg/dL or LDL-C ≥ 60 mg/dL if lipoprotein (a) &gt; 30 mg/ dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Gadolinium or PCSK9 inhibitor allergy&#xD;
&#xD;
          -  Acute or chronic kidney disease with eGFR&lt;30 ml/min/1.73m2&#xD;
&#xD;
          -  Pacemaker or other MRI contraindications per American College of Radiology guidelines&#xD;
&#xD;
          -  Inability to return for 78 week follow-up clinic visit and vwMRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Liebeskind, M.D.</last_name>
    <phone>310-963-5539</phone>
    <email>dliebeskind@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Liebeskind, MD</last_name>
      <phone>310-963-5539</phone>
      <email>dliebeskind@mednet.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>David Liebeskind</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Intracranial Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

